deltatrials
Completed OBSERVATIONAL NCT01362426

Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)

A Quality Use of Medicine Clinical Registry to Assess Clinical Outcomes in Patients With Schizophrenia Treated With Intramuscular Injections of Paliperidone Palmitate

Sponsor: Janssen-Cilag Pty Ltd

Conditions Schizophrenia
Interventions paliperidone palmitate
Updated 7 times since 2017 Last updated: Mar 9, 2016 Started: Mar 31, 2011 Primary completion: May 31, 2013 Completion: May 31, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Schizophrenia and is currently completed. Janssen-Cilag Pty Ltd leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Apr 2018 · 14 months · monthly snapshotCompleted~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed

  2. Jul 2024 — Sep 2024 [monthly]

    Completed

  3. Jan 2021 — Jul 2024 [monthly]

    Completed

  4. Jun 2018 — Jan 2021 [monthly]

    Completed

  5. Apr 2018 — Jun 2018 [monthly]

    Completed

    Phase: PHASE4 → None

▶ Show 2 earlier versions

  1. Feb 2017 — Apr 2018 [monthly]

    Completed PHASE4

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen-Cilag Pty Ltd
Data source: Janssen-Cilag Pty Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations